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Abstract
Background: Neuroblastoma is a childhood malignancy of sympathetic embryonal origin. A high potential for differentiation is
a hallmark of neuroblastoma cells. We have previously presented data to suggest that in situ differentiation in tumors frequently
proceeds along the chromaffin lineage and that decreased oxygen (hypoxia) plays a role in this. Here we explore the utility of
Neuro-Endocrine Secretory Protein 55 (NESP55), a novel member of the chromogranin family, as a marker for this process.
Methodology/Principal Findings: Immunohistochemical analyses and in situ hybridizations were performed on human fetal
tissues, mouse xenografts of human neuroblastoma cell lines, and on specimens of human neuroblastoma/ganglioneuroma.
Effects of anaerobic exposure on gene expression by cultured neuroblastoma cells was analyzed with quantitative real-time
PCR. Fetal sympathetic nervous system expression of NESP55 was shown to be specific for chromaffin cell types. In
experimental and clinical neuroblastoma NESP55 immunoreactivity was specific for regions of chronic hypoxia. NESP55
expression also correlated strikingly with morphological evidence of differentiation and with other chromaffin-specific
patterns of gene expression, including IGF2 and HIF2a. Anaerobic culture of five neuroblastoma cell lines resulted in an 18.9-
fold mean up-regulation of NESP55.
Conclusions/Significance: The data confirms that chronic tumor hypoxia is a key microenvironmental factor for
neuroblastoma cell differentiation, causing induction of chromaffin features and NESP55 provides a reliable marker for this
neuronal to neuroendocrine transition. The hypoxia-induced phenotype is the predominant form of differentiation in
stroma-poor tumors, while in stroma-rich tumors the chromaffin phenotype coexists with ganglion cell-like differentiation.
The findings provide new insights into the biological diversity which is a striking feature of this group of tumors.
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Introduction
‘‘Neuroblastoma, a genetically and clinically diverse malignancy
of infancy and early childhood, is derived from sympathetic
precursor cells within sympathetic ganglia or the adrenal medulla
[1].’’ Neuroblastoma cells have a remarkably retained capacity for
sympathetic differentiation, both on the basis of histological
analysis and clinically through well-documented complete remis-
sions due to spontaneous maturation of residual tumor tissue. The
molecular mechanisms underlying such differentiation are not
clearly understood, but in vitro similar changes are induced by
retinoic acid analogues [2], phorbol esters [3] or Schwann cell co-
culture [4] and the neurotrophin pathway is considered important
[5]. In addition to the accepted notion that neuroblastoma
differentiates towards a sympathetic ganglion cell phenotype in
vivo [6] and in vitro [7], recent evidence has suggested a
neuroendocrine maturation pathway with acquisition of chromaf-
fin features. We previously showed that certain characteristics of
sympathetic neuroendocrine cells [8] are frequent in neuroblas-
toma [9,10] Interestingly these occur centrally within tumor
nodules and in perinecrotic areas, representing regions of chronic
tumor hypoxia and in vitro these neuroendocrine features are
highly induced by hypoxia [11,12].
Diffusion-limited chronic hypoxia is very common in solid
tumors. In neoplastic tissues increased cell proliferation frequently
outpaces angiogenesis, resulting in tumor cells extending beyond
the oxygenation zones that surround blood vessels. This is
exacerbated by the high metabolic demands of tumor cells, and
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unreliable vessel perfusion [13,14]. Reduced oxygenation elicits
activation of Hypoxia-Inducible Factors (HIFs), representing an
evolutionarily conserved physiological response which coordinates
a range of adaptive changes in gene expression and cross-
communicates with other signaling pathways [13,15,16]. The
consequences of tumor hypoxia are increasingly recognized as an
important aspect of cancer biology. Among other effects, hypoxia
promotes resistance to chemotherapeutic agents and radiotherapy,
increases angiogenesis, and can drive tumor progression and
metastasis [17–21]. Its role in altering cell differentiation
programmes has received limited attention, and is likely to be
dependent on cell context.
In our previous characterization of the hypoxic phenotype in
neuroblastoma we employed two markers, IGF2 and chromogra-
nin A [9,12,22]. Within the fetal sympathetic nervous system IGF2
expression is specific and sensitive for chromaffin cell types [8], but
lacks an obvious link to chromaffin function. In neuroblastoma
IGF2 expression is an excellent marker for hypoxia, with more
than 100-fold induction reported [12]. Chromogranin A is a major
constituent of neurosecretory granules and is therefore an
established marker for neuroendocrine cell function [23,24]. In
clinical neuroblastoma chromogranin A immunoreactivity is
associated with tumor hypoxia, but with less dynamic range than
IGF2 expression. In evaluating the role of hypoxia in neuroblas-
toma, and the extent to which it results in acquisition of a
neuroendocrine phenotype, we and others [7] consider identifying
additional reliable markers to be essential.
Recently, Neuro-Endocrine Secretory Protein 55 (NESP55), a
novel member of the chromogranin family [25,26], was found to
be co-expressed with chromogranin A in neuroblastoma [27]. The
aim of this study was to explore the chromaffin marker qualities of
NESP55 during human development and whether its presence in
neuroblastoma may be a consequence of tumor hypoxia. Our data
shows that NESP55 is a highly specific marker for chromaffin cell
types during development and strongly support our hypothesis that
its expression in neuroblastoma is a function of tumor hypoxia.
Materials and Methods
Ethics statement
Animal experiments were approved by the regional animal
ethics committee (Uppsala’s Ethical Committee on Animal
Experiments; approval C70/7), and all testing of clinical tumors
and fetal tissues was approved by the regional human ethics
committee (Regional Ethical Review Board in Uppsala; approval
2007/070). Written informed consent was obtained from families
of surviving children.
Cell culture
The human neuroblastoma cell lines Kelly [28], SK-N-BE(2)
(ATCC number CRL-2271), SH-SY5Y (ATCC number CRL-
2266), SK-N-FI (ATCC number CRL-2142), and LAN-5 [28],
and the human medulloblastoma D324 Med [29] and supraten-
torial PNET PFSK1 (ATCC number CRL-2060) cell lines were
cultured in Eagles minimal essential or RPMI medium supple-
mented with 10% fetal calf serum, glutamine and antibiotics. For
hypoxia, cells at 30% cell density were incubated for 40 hours in
sealed chambers designed for anaerobic bacterial culture (Gas-
PacTM system, BD Biosciences, San Jose, CA, USA). 35 ml
medium was added to the 10 cm diameter culture dishes prior to
incubation. Anaerobic conditions were reached in the gas phase
after approximately three hours. Cells were viable following this
exposure, as reported previously [12].
Real-time PCR analyses
Total RNA was prepared with TRIZOLHReagent (invitro-
genTM, Sweden). RNA purity was controlled with the 2100
BioanalyzerTM system (Agilent Technologies, Inc., Santa Clara,
CA, USA). After treatment with amplification grade DNase I
(invitrogenTM), cDNAs were produced using Oligo dT primers
(invitrogenTM, Sweden), M-MuLV RT and recommended buffers
(New England Biolabs Inc, USA). Real-time PCR was performed
with SYBR Green (Applied Biosystems, Applera Sweden).
Samples were run at 95uC for 10 minutes followed by 45 cycles
of 95uC, 15 seconds and 60uC, one minute. The following primers
were used : NESP55: forward AAGCCCGAGGACAAAGATCC,
reverse TTTGGCTTGCAGCGACG, IGF2: forward TTCCG-
GACAACTTCCCCAG, reverse TGGACTGCTTCCAGGTG-
TCA, HIF1a: forward TTGGAACATTATTACAGCAGCCAG,
reverse CACTAGATTTGCATCCTTTTACACG, HIF2a: for-
ward AGGACTACAGCCTGTCGTCAGC, reverse AAATGA-
GGGCCCGAGCA, NOTCH1: forward CACGGATCATATG-
GACCGC, reverse CCAGGTTGTACTCGTCCAGCA, CHRO-
MOGRANIN A: forward GGTGGCAGGCAAAGAGAGAA, re-
verse ACTCTCGCCTTTCCGGATCT, HES1: forward GGCG-
GCTAAGGTGTTTGGA, reverse AAGGCCCCGTTGGGA-
AT, ID2: forward ATCCTGCAGCACGTCATCG, reverse
GACAATAGTGGGATCCGAGTCC, b-ACTIN: forward ATG-
GATGATGATATCGCCGC, reverse AAGCCGGCCTTGCA-
CAT, RPS28: forward ACCGGTTCTCAGGGACAGTG, re-
verse GATGATGGATCGGCTCGTGT. PCR products were
checked for expected size. Results are the mean of two triplicate
measurements. To identify an appropriate mRNA species for
normalization of values we performed RPS28 and b-actin rt-qPCR
of normoxic and anaerobic samples from all cell lines. Variations
in RPS28 expression between the two conditions were insignificant
in all cell lines, whereas the b-actin analyses indicated robust
hypoxic down-regulation. Therefore triplicate measurement of
RPS28 mRNA was chosen for normalization of each sample.
Experimental tumors
Subcutaneous xenograft tumors were generated in immu-
nodeficient NMRINU-M mice (Taconic Europe) by injecting
7–10 week old female animals with 20–50 million cells in each
hind leg. After reaching a maximum size of 1.5 ml, tumors
were perfusion fixed and processed to 3 mm serial sections as
described [12].
Clinical tumors
Serial 3–5 mm sections were obtained from routinely processed
surgical specimens of 24 neuroblastomas and 2 ganglioneuromas.
INSS criteria [30] were used for clinical staging. 21 neuroblastoma
specimens showed stroma-poor histology and 3 mixed histology
with stroma-poor and stroma-rich regions. The samples repre-
sented a wide clinical spectrum, with particular focus on high-risk
disease. Serial sections of all tumors were evaluated immunohis-
tochemically for presence of NESP55, chromogranin A and with in
situ hybridization for expression of VEGFA and IGF2. Analyses
were repeated if the initial result was negative. NESP55 in situ
hybridization was performed on eleven tumors.
Control tumor specimens
Serial sections were produced from the following pediatric
tumors of nervous system origin: 13 gliomas (high and low grade),
9 medulloblastomas, 5 supratentorial primitive neuroectodermal
tumors, 4 ependymomas, 2 oligodendrogliomas and 2 gang-
liogliomas.
NESP55 in Neuroblastoma
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Human fetal specimens
Serial 3 mm sections were produced from six specimens of
formalin fixed/paraffin embedded human fetal tissues containing
retroperitoneal sympathetic structures. Developmental ages were:
6, 9, 12 (two specimens), 18 weeks and term.
In situ hybridization
35S-aUTP (GE Health Care, Uppsala, Sweden)-labeled probes
were generated with specific activity of ,250 Ci/mole probe.
Templates were: NESP55: a 874 bp Pst1/Bam H1 cDNA
fragment of the hGAI34 clone [31]. HIF1a: a Bgl2/EcoR1
cDNA fragment spanning amino acids 28 to 329 of the coding
region, which generated a 255 bp template at linearization with
Sal1. HIF2a: a 220 bp EcoR1/Bam H1 cDNA fragment
(nucleotides 2542–2762 of sequence accession no. U81984).
Chromogranin A: a 240 bp H9/P1 cDNA fragment of the human
gene (gift from Stefan Wennstro¨m, O¨rebro University, Sweden).
IGF2, VEGFA165, GAP43, b-actin antisense, and IGF2 sense
probes were generated as described [12]. Riboprobes, at 10–
80.000 CPM/ml were hybridized to sections overnight at 56uC
and washed under hybridization-stringent conditions before
RNase treatment, as described [32]. Photographic emulsion
(NTBII; Eastman Kodak Co., Rochester), diluted 1:1 in 2%
glycerol, was applied and slides were developed after 1–3 months
exposure.
Immunohistochemical analyses
Antigens were detected as follows: NESP55: antisera were
raised in rabbits immunized with a synthetic C-terminal fragment
of bovine NESP55 (GAIPIRRH) coupled to keyhole limpet
haemocyanin, and affinity purified using the GAIPIRRH
epitope. The specificity of the NESP55 antibodies had first been
tested on human brain tissue with epitope-adsorbed antibodies,
which was repeated on the fetal specimens in this study using
adsorbed and non-adsorbed antibodies from the same batch at a
four-fold higher concentration than used for all other NESP55
immunohistochemical analyses (1:250 vs 1:1000 dilution). The
specificity of the affinity-purified anti NESP55 antibodies was also
tested on brain sections from nesp55 knock-out mice (kindly
provided by Gavin Kelsey). Chromogranin A: monoclonal
antibody LK2H10 diluted 1:500 (Lab Vision/NeoMarkers/
AHdiagnostics, Sweden, #MS-324-P). For detection of NESP55
and chromogranin A slides were microwave treated in TE buffer
pH 9 (Dako Sweden, #S2367) for 109 at 750 W, followed by 159
at 350 W, then rinsed and run in a DAKO Autostainer plus
which included a blocking step, 30 minutes of primary antibody
incubation, 30 minutes amplification with the Dako REAL
EnVision System (Dako Sweden, #K5007) and 10 minutes
development. For negative controls the primary antibody was
omitted. HIF1a and HIF2a: Primary antibodies were: mouse
monoclonal antihuman HIF1a H1a67 (Neomarkers, Fremont,
CA, USA), and 1/1000 rabbit polyclonal anti-mouse HIF2a´ PM8
antiserum, applied as described [33].
Histological measurements
Distances from vascular stroma to regions of NESP55
immunreactivity were measured using digital images of NESP55-
stained tumor sections and an index scale. Representative
xenografts and clinical tumors were chosen based on presence of
well demarcated regions of NESP55 immunoreactivity. Measure
points were capillary endothelial layer and first layer of NESP55
immunoreactive tumor cells. A mean score, based on ten
measurements, was made from each tumor.
Statistical methods
Independent sample t-test was applied for determination of the
significance of rt-qPCR data using SPSS software.
Results
Human fetal expression of NESP55
In specimens representing developmental weeks six through
eighteen NESP55 immunoreactivity was specific and strong for
chromaffin constituents of the sympathetic nervous system – i.e.
paraganglia cells (Fig. 1: A) chromaffin cells of the adrenal medulla
(Fig. 1: D) and small intensely fluorescent (SIF) cells [34] of sympathetic
ganglia (Fig. 1: C). During this late embryonic/early fetal phase of
develoment, neuronal cells of sympathetic ganglia were morpho-
logically primitive and lacked NESP55 immunoreactivity (Fig. 1: A
and C), as was also the case throughout development for nests of
primitive neuroblastic cells of the adrenal medulla (Fig. 1: D). At
term, when sympathetic ganglion cells are morphologically more
mature, NESP55 immunoreactivity was still essentially chromaf-
fin-specific under standard testing (Fig. 1: E and F), although weak
immunoreactivity was found in occasional ganglion cells. When
testing at a four-fold increased anti-NESP55 antibody concentra-
tion a weak and general cytoplasmic immunoreactivity was evident
at this stage of ganglion cell differentiation (Fig. 1: G). The small
size of SIF cells, relative to ganglion cells, was also evident at this
developmental stage (Fig. 1: F and G). Apart from their strong
NESP55 immunoreactivity of both cell soma and cell process(es),
SIF cells displayed a characteristic pattern of nuclear staining with
punctate basophilia in a pale background (Fig. 1: G), characteristic
of chromaffin cells [35]. NESP55 expressing cell types outside the
sympathetic nervous system were: motor neurons of the spinal
medulla, striated muscle, metanephric blastema, and macula
densa-like cells associated with the glomerular tuft (Fig. 1: A and
data not shown). NESP55 in situ hybridization revealed an
identical cell type-specific pattern of expression to the immuno-
histochemical analyses (Fig. 1: B). Immunoreactivity was almost
completely abolished following epitope-adsorption, with no
evident difference in cellular specificity of the remaining weak
signal (data not shown). No immunoreactivity was seen with non-
blocked antibodies applied to brain sections from nesp55 knock-out
mice (data not shown). Therefore the NESP55 antibodies are both
specific and sensitive for detection of NESP55.
These findings were compared with chromogranin A immuno-
reactivity in consecutive sections. Analogous to NESP55, immu-
noreactivity to chromogranin A by chromaffin cell types was
intense (Fig. 2: A). In contrast, significant chromogranin A
immunoreactivity of sympathetic neuronal cell processes was
found at all stages of development, establishing that chromogranin
A is a less specific marker for chromaffin cell types than NESP55
(compare Fig. 2 and Fig. 1: E and F). Furthermore, the cytoplasm
of morphologically mature ganglion cells displayed a different
staining pattern for chromogranin A, with patchy and mainly peri-
nuclear signal (compare Fig. 2: B and Fig. 1: G).
These results indicate that NESP55 is a sensitive chromaffin
marker in the early human sympathetic nervous system, with a
specificity superior to that of chromogranin A.
Expression of NESP55 and other genes of interest in
neuroblastoma under anaerobic cell culture
In order to test whether NESP55 expression was influenced by
hypoxia in neuroblastoma, Kelly, SK-N-BE(2), SH-SY5Y, SK-N-FI,
and LAN-5 cells were tested with quantitative real-time PCR after
exposure to anaerobic conditions. Up-regulation of NESP55 mRNA
levels was seen in all cell lines, ranging from 3- to 53-fold (Table 1).
NESP55 in Neuroblastoma
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We also examined expression of other genes of interest (Table 1):
IGF2 was massively (.500-fold) up-regulated by hypoxia in SH-
SY5Y and LAN-5 cells from very low levels under standard
conditions. Despite higher levels of basal expression in the remaining
three cell lines, two of these also displayed robust hypoxic IGF2 up-
regulation, comparable to that of NESP55. HIF regulation is
primarily through oxygen-dependent hydroxylation of the alpha
subunits, which enables their efficient degradation in the presence of
oxygen [36]. HIF-1a and HIF-2a are non-redundant, have
differential effects on target genes and are expressed in different
Figure 1. Sympathetic nervous system expression of NESP55 during human development. A and B: NESP55 immunohistochemistry (A)
and NESP55 in situ hybridization (B) results from consecutive mid-abdominal sections of a nine week old fetus (developmental age) containing the
organ of Zuckerkandl, i. e. the largest sympathetic paraganglia of the body, and sympathetic trunk ganglia. Other organs are: small intestine, kidneys,
aorta, spinal cord, vertebra and paravertebral muscles. C and D: NESP55 immunoreactivity of sympathetic cell types in (C): an abdominal sympathetic
trunk ganglion at age nine weeks, and (D): of the adrenal medulla at 18 weeks of development. Panel C is a high power view of boxed region in A and
shows pericentric presence of NESP55 immunoreactive small intensely fluorescent (SIF) cells. Panel D shows adrenal tissue containing nests of
sympathetic neuroblastic cells and NESP55 immunoreactive medullary chromaffin cells mixed with cortical cells. E–G: NESP55 immunoreactivity of
para-adrenal sympathetic tissue of a term fetus. Panel E depicts a sympathetic paraganglion and an adjacent sympathetic ganglion. Panel F is a high
power view of a sympathetic ganglion of the same specimen. G: Same ganglion as in F, tested with a four-fold higher anti-NESP55 antibody
concentration. Insert is a high power view of an indicated SIF cell. Symbols: Large black arrowheads: sympathetic paraganglia; arrows: sympathetic
ganglia, red arrowheads: SIF cells, small black arrowheads: ganglion cells.
doi:10.1371/journal.pone.0012825.g001
NESP55 in Neuroblastoma
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cell types [33,37,38]. Expression of HIFa genes is usually not greatly
influenced by hypoxia at the mRNA level [39]. Interestingly, in
neuroblastoma cells we did find a clear oxygen dependence of these
transcripts: HIF2a transcript levels were significantly induced by
anoxia in SK-N-BE(2), SH-SY5Y, and SK-N-FI cells, whereas
HIF1a was down-regulated in all five neuroblastoma cell lines. A
similar finding of interest was hypoxic down-regulation of b-actin
expression in all cell lines, which excluded its use as an internal
standard for normalization of our values (data not shown).
Furthermore, our data indicated that both Hairy Enhancer of Split
homolog-1 (HES1), and Inhibitor of DNA binding 2 (ID2) transcripts were
down-regulated by anaerobic hypoxia in all cell lines, whereas
NOTCH1 was up-regulated in four of the cell lines (Table 1).
However, the real-time PCR data indicated very low expression
levels of NOTCH1. These three genes were tested because of their
previously reported roles in modulating neuroblastoma phenotype in
association with reduced cellular oxygen tension [40]. The
expression of CHROMOGRANIN A was down-regulated by hypoxia
in four of the cell lines under these culture conditions (Table 1).
Expression of NESP55 in tumor xenografts, relationship
to hypoxia markers and to vascular stroma
Next, we tested whether regional hypoxia in solid tumours would
induce expression of NESP55. Therefore, we generated xenograft
tumors in immunodeficient mice from the cell lines tested with real-
time PCR. Serial sections were prepared and the spatial distribution
of NESP55 immunoreactive cells was studied in relation to the
vascular stroma and to expression of markers for hypoxia and
phenotype: nuclear HIF2a immunoreactivity was selected as an
operational definition of a cellular response to hypoxia and
expression of VEGFA and of IGF2 were used as independent
hypoxia markers, previously validated in neuroblastoma [11,12,41].
The mRNA expressions of NESP55, HIF1a, and HIF2a were also
studied with in situ hybridization. In addition, chromogranin A
expression was studied both immunohistochemically and with in
situ hybridization. Finally, we studied the distribution of Growth-
Associated Protein 43 (GAP 43) expressing cells, which is a marker for
axonal growth [42] and an established marker for an early
sympathetic neuronal phenotype in neuroblastoma [12,43]. These
histological findings are summarized in Table 2.
As exemplified in Figure 3, immunoreactivity for NESP55 was
clearly heterogeneous in the various tumor xenografts and the
proportion of cells that were labelled differed between tumors.
NESP55 immunoreactive regions coincided strikingly with regions
displaying nuclear immunoreactivity to HIF2a (Fig. 3), implying
that they were hypoxic. The concordance between IGF2 and
VEGFA expressing regions and their striking overlap with regions
of nuclear HIF2a accumulation (Fig. 3) is consistent with each of
these being activated by hypoxia. SK-N-FI was the only cell line
generating tumors with more generalized NESP55 immunoreac-
tivity. In this tumor type more intense staining was observed in
regions with HIF2a staining (Fig. 3). Examination under higher
Figure 2. Chromogranin A immunoreactivity of the human fetal sympathetic nervous system. A: Sympathetic paraganglion and adjacent
sympathetic ganglion of a term fetus. Same region as shown in Figure 1 panel E, analyzed in a consecutive section. B: High-power view of a
sympathetic ganglion from the same section. Symbols: black arrowhead: sympathetic paraganglion; arrow: sympathetic ganglion, red arrowhead: SIF
cell. Black double arrowheads indicate axonal stainings and red double arrowheads indicate perinuclear stainings of ganglion cells.
doi:10.1371/journal.pone.0012825.g002
Table 1. Effects of anoxia on expression of NESP55 and of other genes in five neuroblastoma cell lines.
Kelly SK-N-BE(2) SH-SY5Y SK-N-FI LAN5
NESP55 4.5 (.34**) 21 (3.3*) 53 (.97***) 14 (1.4*) 3.0 (.36*)
IGF2 2.1 (.66 ns) 9.3 (.83***) 577 (40***) 11 (.78***) 1055 (177**)
HIF2a 0.39(.011***) 1.6 (.16**) 1.3 (.052***) 3.0 (.29**) 0.61 (.17 ns)
HIF1a 0.25 (.014***) 0.22(.015***) 0.53 (.085**) 0.20 (.008***) 0.25(.023***)
NOTCH1 13 (1.3***) 0.50(.039***) 9.5 (2.9*) 18 (2.0***) 4.4 (.63**)
HES1 0.11 (.015***) 0.08(.006***) 0.17(.013***) 0.17 (.013***) 0.08(.005***)
ID2 0.09 (.008***) 0.16(.011***) 0.47 (.15***) 0.39 (.021***) 0.40(.034***)
CgA 0.13 (.089***) 0.40(.083***) 0.87 (.18 ns) 0.30 (.024***) 0.63(.039***)
Results are relative to levels of control cells cultured in parallel at ambient air oxygen tension (‘‘normoxia’’) and represent means of two quantitative real-time PCR
analyses, each performed in triplicate. Symbols: *: p,.05; **: p,.01; ***: p,.001; ns: non-significant difference. CgA: chromogranin A. Numbers within brackets refer to
standard error of mean.
doi:10.1371/journal.pone.0012825.t001
NESP55 in Neuroblastoma
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magnification showed that the increased NESP55 immunoreac-
tivity in hypoxic regions of SK-N-FI-derived tumors was
contributed to by increased signal intensity in each cell, and an
increased proportion of positive cells (Fig. 4). In other tumors there
was also strong spatial correlation between NESP55 immunore-
activity and nuclear HIF2a at the cellular level (Fig. 4 and Table 2).
It was also evident that NESP55 and HIF2a immunoreactivities
were dependent upon tumor cell distance from blood vessels
(Fig. 4). Mean distances to NESP55 immunoreactive cells, as
previously defined, were 50 mm, 93 mm and 50 mm for xenografts
derived from Kelly, SH-SY5Y and SK-N-BE(2) cells, respectively.
At further distances from the blood vessels the NESP55/HIF2a
positive regions frequently bordered on areas of tumor necrosis
(Fig. 3: Kelly and Fig. 4: Kelly, SK-N-BE(2) and SH-SY5Y). This
distribution of HIF2a immunoreactive tumor cells, in combination
with the well-characterised hypoxia-dependent stabilisation of
HIF2aare consistent with the notion that regions with combined
NESP55 and HIF2a immunoreactivity represent chronically
hypoxic tumor cells, caused by the limited range of oxygen
diffusion from the microvascular circulation.
Nuclear immunoreactivity of HIF1a coincided with that of
HIF2a in all neuroblastoma xenografts (Fig. 4, Table 2), albeit
with lower intensity which was particularly evident in tumors
derived from Kelly cells. The strikingly similar distribution of
immunoreactivity for HIF1a and HIF2a in neuroblastoma
supports the validity of our hypoxia markers.
NESP55-independent evidence for a hypoxia-dependent
shift of sympathetic phenotype in neuroblastoma
Interestingly, areas of predicted hypoxia were associated with
increased mRNA expression of HIF-2a in tumor xenografts and
there was also evidence of this in several lines in our anaerobic
culture studies (Fig. 5: A; Tab. 1 and 2). Together with IGF2
expression, this observation provides some independent support
for a neuroendocrine tumor phenotype of hypoxic neuroblastoma
cells in view of the chromaffin-specific expression of HIF2a [44,45]
and IGF2 [8,9] in fetal tissues (also shown in Fig. 5: A). A
complementary sign of a shift in phenotype in hypoxic regions was
provided by GAP 43 in situ hybridization. This marker of an early
neuronal phenotype was markedly decreased in hypoxic tumor
regions, parallel to induced HIF2a and IGF2 (Fig. 5: A and
Table 2). A more traditional neuroendocrine feature in regions of
tumor hypoxia was observed in tumors generated from SK-N-FI
cells: in this tumor type chromogranin A expression was hypoxia-
dependent, both at the protein and the transcriptional levels (Fig. 5:
B and Table 2).
Expression of NESP55 in clinical neuroblastoma and
ganglioneuroma
We then proceeded to examine NESP55 expression and its
relation to hypoxia in clinical specimens of neuroblastoma.
Expression of IGF2 and VEGFA were used as markers of a
hypoxic response in our histological testing of these specimens. All
but two tumors displayed NESP55 immunoreactive cells (Table 3).
NESP55 in situ hybridization showed results identical to those of
NESP55 immunohistochemistry, supporting the accuracy of the
immunoanalysis (data not shown). The proportions of immuno-
reactive tumor cells varied between tumors and expression was
regional with an abrupt onset at distances varying from 87 to
160 mm (median 115 mm) from the vascular stroma, which was
strikingly coordinated with expression of IGF2 (Fig. 6: A and B).
Based on co-expression with VEGFA and/or IGF2, cells expressing
Table 2. Histological evidence of hypoxia-dependence of expression of NESP55 and of other genes in neuroblastoma xenografts.
Kelly SK-N-BE(2) SH-SY5Y SK-N-FI LAN5
Candidate markers of phenotype
NESP55-IHC X(sp) X(sp) X(sp) X(gr/w) X*
NESP55-ISH ND ND X(gr/str) ND ND
IGF2-ISH X(sp) X(gr/str) X(sp) X(gr/str) X(sp)
HIF2,a-ISH X(gr/w) X(gr/str) X(gr/str) X(sp) X(gr/w)
GAP 43-ISH Y(partial) Y(partial) Y(complete) Y(partial) =
CgA-IHC = = = X(sp) =
CgA-ISH = = = X(gr/str) =
HIF1,a-ISH ND ND Y(partial) = ND
b-actin-ISH ND = Y(partial) ND ND
Hypoxia markers
HIF2aIHC X(ref) X(ref) X(ref) X(ref) X(ref)
HIF1aIHC X(sp) X(sp) X(sp) X(sp) X(sp)
VEGFA-ISH X(sp) X(sp) X(sp) X(sp) X(sp)
Nuclear HIF2a immunoreactivity was used as operational definition of hypoxia. Serial sections were used to compare the different results.
Abbreviations and symbols: IHC: immunohistochemistry; ISH: in situ hybridization; CgA: chromogranin A.
X(sp): positivity specific for regions of chronic hypoxia.
X(gr/w): weak positive gradient of expression in regions of chronic hypoxia but expression not specific to these regions.
X*: few positive cells, but exclusively in regions of chronic hypoxia.
ND: not analyzed.
X(gr/str): strong positive gradient of expression in regions of chronic hypoxia but expression not specific to these regions.
Y(partial): partial down-regulation in regions of chronic hypoxia.
Y(complete): complete down-regulation in regions of chronic hypoxia.
= : no discernible chronic hypoxia-dependence of expression intensity.
X(ref): reference method for identification of regions of chronic hypoxia.
doi:10.1371/journal.pone.0012825.t002
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Figure 3. NESP55 immunoreactivity and histological evidence of hypoxia in neuroblastoma xenografts. Columns represent NESP55/
HIF2a immunoreactivities and IGF2/VEGFA in situ hybridization (ISH) results, as shown. Rows represent different cell lines, as described. In each row
the same tumor region is shown for the different analyses. NESP55/HIF2a results are produced from consecutive sections. IGF2/VEGFA results are from
consecutive sections that are adjacent, but not consecutive, to the former sections. HIF2a immunoreactivity and IGF2/VEGFA expressions were chosen
as markers for cellular hypoxia. IGF2 ISH results and VEGFA ISH results for Kelly are shown in brightfield view (silver grains appear in black). VEGFA
expression in SK-N-BE(2) is represented by an x-ray film autoradiography and VEGFA ISH results for SH-SY5Y and SK-N-FI xenografts are shown in
darkfield view (silver grains appear in white). Symbol: n: areas of necrosis.
doi:10.1371/journal.pone.0012825.g003
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NESP55 were identified as hypoxic in seventeen of the 24
specimens in which there was positive signal (Table 3). We did not
observe a correlation between hypoxic NESP55 expression and
the prognostic category of neuroblastoma. Interestingly we
observed hypoxic NESP55 expression in tumors from all
categories suggesting that there is not a strong relationship to
prognostic category, but the sample size was relatively small and so
we cannot exclude such an association (Table 3; exemplified in
Fig. 6). Specific locations and cytological characteristics of
NESP55 positive tumor cells were evident: typically, and in
analogy to the xenografts, NESP55 positive cells were positioned
at a distance from the fibrovascular stroma (Fig. 6: B and Fig. 7:
B). Morphological characteristics of these cells were: an enlarged
and eosinophilic cell soma (Fig. 7: A and C), nuclear enlargement
and pallor (Fig. 7: C), differences in cell orientation (Fig.7: A and
B), and more abundant processes and neuropil, as compared to
adjacent tumor cells (Fig. 7: A–D). The nuclear characteristics
were reminiscent of chromaffin cell types (compare Fig. 1: G) and
differed clearly from those of mature ganglion cells. In ganglio-
neuroma small NESP55 positive cells with the same nuclear
characteristics (Fig. 7: E–G) were found mingled with larger tumor
cells with weaker, or absent, NESP55 immunoreactivity and a
ganglion cell-like nuclear morphology (Fig. 7: E, F and H). Hence,
we found evidence for the co-existence of two types of
differentiation in stroma-rich tumors.
Although NESP55 immunoreactivity and IGF2 expression were
tightly linked in most tumors, this correlation was not observed in
seven of the NESP55 positive tumors. Tumors from patients who
had already received treatment were strikingly over-represented in
this category (Table 3), so it is possible that treatment-related
effects had altered gene expression patterns, resulting in decreased
VEGFA and IGF2 in situ hybridization results in these tumors.
However, two of them were particularly interesting because of
general NESP55 positivity, independent of distance from fibro-
vascular stroma. This would support the possibility that hypoxia-
independent NESP55 expression does occur in some neuroblas-
tomas. Clinically, these two tumors were a metastatic neuroblas-
toma and a ganglioneuroma. In general, chromogranin A
immunoreactivity was also observed in hypoxic tumor cells but
the gradients in expression were less marked than NESP55 (Fig. 8).
NESP55 expression in pediatric brain tumor specimens
and cell lines
We considered the possibility that NESP55 expression may be
induced in other tumors of neuronal origin in response to hypoxia,
Figure 4. Arrangements of NESP55, HIF2a and HIF1a immunoreactive cells in neuroblastoma xenografts related to fibro-vascular
stroma. Columns represent the different immunohistochemical analyses, as indicated, and rows show a tumor region, analyzed in consecutive
sections, of mouse xenografts derived from four different neuroblastoma cell lines, as indicated. Symbols: n: areas of necrosis; asterisks: vascular
lumina.
doi:10.1371/journal.pone.0012825.g004
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which might suggest it was a general response to hypoxia as
opposed to a context-specific phenomenon consistent with
chromaffin differentiation. 35 pediatric brain tumors were
therefore tested for presence of chronically hypoxic regions by
identification of graded VEGFA signals with ISH and, when
present, NESP55 IHC was performed on consecutive sections.
Figure 5. NESP55-independent evidence of a chromaffin hypoxic phenotype in neuroblastoma xenografts. A: Columns show HIF2a,
IGF2 and GAP 43 in situ hybridization results, as indicated. The specificities of these expressions within the early sympathetic nervous system are
shown in the upper row, representing consecutive sections of a 12 week fetal specimen containing a sympathetic ganglion and a sympathetic
paraganglion, as indicated. The rows below represent consecutive sections from three different neuroblastoma xenograft tumors, as indicated. Silver
grains appear in black in panels showing IGF2 expression (brightfield illumination). In all other panels silver grains appear in white (darkfield
illumination). IGF2 ISH is used here as a combined marker for a chromaffin phenotype and for tumor hypoxia. Symbols: arrows: sympathetic ganglion;
arrowheads: sympathetic paraganglion; asterisks: vascular structures. B: Chromogranin A expression in a SK-N-FI neuroblastoma xenograft. Left
and middle panels depict chromogranin A immunoreactivity at two different magnifications. Right panel shows a chromogranin A in situ hybridization
result in darkfield view from a consecutive section. Middle and right panels represent the same tumor region as depicted in the bottom row of
Fig. 5: A.
doi:10.1371/journal.pone.0012825.g005
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None of the twelve tumors (7 gliomas, 3 supratentorial PNETs, 2
ependymomas) tested with IHC displayed any NESP55 immuno-
reactivity in regions with hypoxia-induced VEGFA expression, or
elsewhere in the tumors. The other 23 tumors did not display
gradients of VEGFA expression and were therefore not tested with
NESP55 IHC. We also tested NESP55 expression under anaerobic
conditions in the human medulloblastoma cell line D324 Med and
in the human supratentorial PNET cell line PFSK1 indicating
insignificant (1.2-fold; standard error of mean .035) or minor (2.4-
fold; standard error of mean .178; p,.001) induction, respectively.
Discussion
Fetal chromaffin physiology and NESP55 as a chromaffin
marker
The mammalian sympathetic nervous system displays a fetal-
specific organization of the chromaffin compartment with the
major constituents being bulky retroperitoneal paraganglia and
abundant SIF cells within sympathetic ganglia [34,35]. These
extra-adrenal chromaffin cells play important roles in fetal oxygen
homeostasis [46] and undergo involution postnatally [35]. We
show here that NESP55 is a marker for a chromaffin phenotype in
the developing human sympathetic nervous system. In the earliest
stages studied, when ganglion cells are still morphologically
immature, its expression was strictly limited to paraganglia cells,
SIF cells, and chromaffin cells of the adrenal medulla. Immuno-
histochemical and in situ hybridization data both indicated
abundant expression at all developmental stages studied, starting
from the late embryonal phase when paraganglia begin to form
(developmental age six weeks). This pattern of expression within
the developing human sympathetic nervous system strongly
resembles that of IGF2 [8,9] and defined NESP55 as a clearly
superior marker for a sympathetic neuroendocrine phenotype
when compared to chromogranin A.
Evidence for a chromaffin hypoxic tumor phenotype in
neuroblastoma provided by NESP55 and by independent
markers
In neuroblastoma NESP55 was commonly expressed and found
mainly in association with diffusion-limited tumor hypoxia. This
provides strong support for our previous suggestion that
neuroblastoma cells respond to hypoxia by shifting towards a
more mature neuroendocrine phenotype. In the current study we
have taken an exhaustive approach to address this phenomenon,
exemplified by the following: First, the specificity and sensitivity of
the anti-NESP55 antibodies we developed were confirmed via
testing epitope adsorbed antibodies, precise correspondence with
NESP55 in situ hybridization, and lack of NESP55 immunoreac-
tivity in brain tissues from nesp55 knock-out mice. Second,
neuroblastoma cell line experiments showed that anoxia strongly
increases expression of NESP55 mRNA in all five cell lines tested,
and that presence of NESP55 protein in the corresponding
xenografts correlated with distance from blood vessels. Third,
independently of our NESP55 data, other changes in gene
expression support a chromaffin phenotype of hypoxic neuroblas-
toma cells: up-regulation of IGF2 and of HIF2a, in particular, was
strong evidence of this, as chromaffin-specific expression within
the sympathetic nervous system of both of these genes was shown
both in this and in previous investigations [9,44,45]. Parallel to
this, hypoxic down-regulation of GAP 43 in the xenografts was
evidence in support of loss of neuronal tumor characteristics.
Although not studied here, this hypoxia-dependence of GAP 43
expression applies also to clinical neuroblastoma/ganglioneuroma
[12]. In the clinical specimens studied here, IGF2 co-expression
with NESP55 was seen in the majority of cases and chromogranin
A/NESP55 co-expression was frequent and was also observed in
xenografts of SK-N-FI cells. Fourth, independent markers for
hypoxia were employed and were congruent with NESP55
expression at the cellular level in tumor tissues. Fifth, we observed
that NESP55 expression was tightly linked to morphological signs
of tumor maturation in clinical tumors, with features resembling
those of SIF cells [34]. Sixth, we excluded the possibility that
hypoxic NESP55 immunoreactivity is a general response to
hypoxia by testing some other pediatric tumors of central nervous
system origin and examining NESP55 expression in two non-
neuroblastoma brain tumor-derived cell lines. We have also tested
48 pediatric brain tumors of different types with in situ
hybridization for IGF2 expression. None of the tested specimens
displayed a hypoxic pattern of IGF2 expression (unpublished data).
These experiments are consistent with hypoxic expression of
NESP55 and of IGF2 representing markers for chromaffin
differentiation in neuroblastoma tissue.
Table 3. Hypoxia-dependence of NESP55 immunoreactivity in clinical variants of neuroblastoma and in ganglioneuroma.
CLINICAL DATA NESP55 expressed NESP55 not expressed1
Hypoxia-dependent NESP55
expression (NESP55/IGF2/
VEGFA co-expression)
No evidence for hypoxia-
dependent NESP55 expression
(IGF2/VEGFA not expressed)1
Signs of hypoxia
(IGF2/VEGFA
expressed
No signs of hypoxia (IGF2/
VEGFA not expressed)1
Clinical group n Alive
Ganglioneuroma 2 2 1(0*) 1(0*) - -
Infant stage 1–3 4 4 3(0*) - - 1(0*)
Stage 4S 1 1 - - 1(0*) -
Stage 3–4.18 mo 18 1 12(3*) 6(6*) - -
Stage 1.18 mo 1 0 1(0*) - - -
TOTAL 26 8 17 7 1 1
NESP55 expression was evaluated by immunohistochemistry and hypoxia dependence by its co-expression with VEGFA and/or IGF2, as determined with in situ
hybridization performed on sections consecutive to those used for the NESP55 analyses.
Abbreviations and symbols: n: number of cases;
1negative results are based on two independent experiments;
*number of tumors subjected to chemotherapy prior to sampling; .18 mo: more than 18 months of age at diagnosis.
doi:10.1371/journal.pone.0012825.t003
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Figure 6. NESP55 immunoreactivity and IGF2 expression in clinical variants of neuroblastoma. A: Low power magnification: First column:
abdominal stage 4 tumor with a poor patient outcome. Second column: abdominal stage 3 tumor of an adolescent. Patient outcome was poor due to
complications after myeloablative therapy. Third column: abdominal infant stage 3 tumor with a favourable clinical outcome. All specimens were
obtained prior to start of chemotherapy. B: High power views of the same sections (boxed regions in A): Symbol: asterisks: fibro-vascular stroma.
doi:10.1371/journal.pone.0012825.g006
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Implications for concepts of differentiation in
neuroblastoma and for neuroblastoma pathology
The present data support the conclusion that chronic tumor
hypoxia alters the phenotype of neuroblastoma cells and that
NESP55 provides an excellent marker to study this phenomenon.
Based on previous studies on IGF2 expression, we have suggested
the term ‘‘chromaffin metaplasia’’ for the change in phenotype
[12], and our present findings are summarized schematically in
Figure 9. The data imply existence of simultaneous processes in
stroma-rich tumors enabling maturation either towards a chro-
maffin or a ganglionic phenotype in neighbouring cells, putatively
reflecting alternative embryonal programmes in autonomic
nervous system development.
Although the chromaffin tumor phenotype in neuroblastoma is
easily revealed by analyzing expression of NESP55 and IGF2, the
corresponding morphological features are relatively inconspicuous.
This is in line with the small cell size and subtle nuclear
characteristics of the SIF cell phenotype, which means that it
would be easily overlooked in pathological examination of
neuroblastoma. It appears that these subtle morphological signs
Figure 7. Morphological features of NESP55 immunoreactive cells in clinical neuroblastoma and in ganglioneuroma. A–C: Favourable
outcome, stroma-poor infant stage 3 neuroblastoma. Boxed region in panel A is shown in panel C. D: prognostically unfavourable, stroma-poor
adolescent stage 4 neuroblastoma. E–H: Stroma-rich ganglioneuroma. G and H show the respective nuclear morphologies of cells indicated in E.
Panels A, C, E, G and H are haematoxylin-eosin stanings and panels B, D and F show NESP55 immunoreactivity. Panels B and F are from sections
consecutive to A and E, respectively. Symbols: asterisks: fibro-vascular stroma, arrowheads: indicate a group of three NESP55 immunoreactive cells,
arrows: indicate a large tumor cell lacking NESP55 immunoreactivity.
doi:10.1371/journal.pone.0012825.g007
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of tumor cell maturation on routine staining previously tended to
be viewed as early signs of ganglionic differentiation (e.g. see
Fig. 1g-i in [6]). The current data implies instead that these
morphological features observed in neuroblastoma pathology
represent a chromaffin phenotype. Significantly, the current data
imply that the chromaffin pathway is the main form of cell
maturation in stroma-poor tumors and implies co-existence of two
differentiation pathways in tumors with a stroma-rich histology.
We consider that this is likely to be a significant insight into
understanding differentiation in neuroblastomas. However we are
not suggesting that this should alter clinical pathology criteria that
are in current use, since the clinical implications (if any) of the very
common process we observe in neuroblastoma are as yet unclear.
Hypoxia-induced chromaffin metaplasia applies across
the clinical spectrum
An important aspect of our findings is that hypoxia-mediated
chromaffin metaplasia appears to occur across the clinical spectrum
of sympathetic neuroblastic tumors, ranging from ganglioneuroma
through to highly aggressive variants of the disease - and that this is
also observed in cell lines. This contrasts with the recently expressed
view that hypoxia induces chromaffin features only in low-risk
tumors, but that in high-risk disease and in cell lines tumor hypoxia
leads to a dedifferentiated tumor state, similar to that of neural crest
cells (reviewed in [7]). This model is not supported by the present
findings since our data is derived mainly from high-risk tumors and
MYCN amplified cell lines, and shows clear evidence of chromaffin
features in these tumors in association with hypoxia. The
dedifferentiated hypoxic state reported by others has been inferred
from studying signaling pathways, but we would caution that the
specificity of these signals as neural crest markers is uncertain, since
the cell population in question is not readily available for study in
the human context. In considering why these studies have reached
rather different conclusions from our own it should also be noted
that we have used anoxia rather than 1–0.5% oxygen in our cell
culture experiments. Importantly, the similarity between the effects
of anoxia in cell culture and our observations in model tumors and
clinical specimens imply that our approach is relevant to the in vivo
setting. Interestingly, amongst NOTCH1, ID2, and HES1 which
were reported to be induced by 1–0.5% oxygen and proposed as
Figure 8. Regional co-expression of NESP55 and chromogranin A in clinical subtypes of neuroblastoma. Each row represents a clinical
subset of sympathetic neuroblastic tumors showing NESP55 and chromogranin A immunoreactivity in consecutive sections, as exemplified in two
separate tumors. The upper two rows represent tumors with a stroma-poor histology and bottom row shows nests of tumor cells within a stroma-rich
environment from two ganglioneuromas. Note a more general membraneous/neuritic chromogranin A immunoreactivity in some of the specimens,
as compared to cytoplasmic staining for chromogranin A in regions of NESP55 immunoreactivity. Abbreviations: CgA: chromogranin A; HR: high-risk
neuroblastoma according to INRG criteria, LR: low-risk neuroblastoma according to INRG criteria; st 4: INSS stage 4 (metastatic); st 2: INSS stage 2; GN:
ganglioneuroma
doi:10.1371/journal.pone.0012825.g008
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mediators of dedifferentiation [40,47] the two latter genes were not
induced under the conditions we used. Although our observations
differ, and we cannot explain this, the conclusions of the studies –
that hypoxia can drive aspects of differentiation and dedifferenti-
ation should not be regarded as necessarily contradictory because it
is plausible that cancer cells simultaneously develop some features
associated with both differentiation and de-differentiation. Although
cultured cell lines exposed to hypoxia/anoxia provide a useful
model system this approach will only recreate some aspects of the
complex situation in human tumors. Our findings are based
primarily on clinical specimens, and it is not surprising that in vitro
studies using clonal cell lines only capture some aspects. A specific
example is that in clinical specimens (and xenografts of one cell line)
we observed a correlation between hypoxia and chromograinin A
expression but exposure to cell lines to anoxia in vitro did not result
in increased expression.
NESP55 in neuroblastoma - concluding remarks and
future prospects
We conclude that expression of NESP55 is a sensitive marker
for hypoxia-dependent chromaffin metaplasia in neuroblastoma,
which represents the dominant form of differentiation in this group
of tumors. Determining the mechanistic link(s) between hypoxia
and chromaffin differentiation will require further studies. The
role of HIF2a should be of particular interest in view of its strong
expression in hypoxic neuroblastoma cells relative to HIF1a and
its expression in chromaffin cell types.
The high specificity and sensitivity of NESP55 for an early
chromaffin phenotype in fetal tissues makes it a valuable
complement to other markers of the sympathetic subphenotype.
Its hypoxia-dependent expression in neuroblastoma may reflect an
important role for hypoxia in the normal development and stress-
adaptation of the fetus. The clinical and therapeutic significance of
such hypoxia-induced chromaffin metaplasia clearly merits further
study, both in terms of embryonal/fetal adaptation to limited
oxygen and in terms of neuroblastoma biology. We envisage that
incorporation of this marker in the diagnostic panel for
neuroblastoma will provide an important tool for improved
diagnostic accuracy and for improved biological understanding
of this complex set of tumors.
Acknowledgments
We are grateful for technical assistance from Ulrika Larsson, Inga Hansson
and Barbro Einarsson and for technical and intellectual support from
Stefan Wennstro¨m.
Author Contributions
Conceived and designed the experiments: FH RFC PHM. Performed the
experiments: FH RFC N MGT. Analyzed the data: FH RFC BS PHM.
Contributed reagents/materials/analysis tools: FH RFC BS MGT PHM.
Wrote the paper: FH PHM. Conceived, designed and performed MOST
of the experiments: FH. Conceived, designed and performed SOME of the
experiments: RFC. Performed R-T PCR: NO¨. Performed HIFalpha
immunohistochemistry: MGBT.
References
1. Brodeur G, Sawada T, Tsuchida Y, Vouˆte P, eds (2000) Neuroblastoma.
Amsterdam: Elsevier. 582 p.
2. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ (2003) Retinoid therapy
of high-risk neuroblastoma. Cancer Lett 197: 185–192.
Figure 9. Schematic summary of the studied effects of diffusion-limited hypoxia in neuroblastoma. x-axis symbolizes the distance from
tumor capillary and y-axis symbolizes the relative levels of marker gene expression and of oxygen tension (pO2). Photo images exemplify the
microvascular-dependence of NESP55 immunoreactivity and of changes in cell morphology. Photo images are from the same tumor region of an
infant neuroblastoma, taken from consecutive sections. Black triangle symbolizes the region of increasing chromaffin metaplasia parallel to
decreasing tissue oxygen tension.
doi:10.1371/journal.pone.0012825.g009
NESP55 in Neuroblastoma
PLoS ONE | www.plosone.org 14 September 2010 | Volume 5 | Issue 9 | e12825
3. Pahlman S, Mamaeva S, Meyerson G, Mattsson ME, Bjelfman C, et al. (1990)
Human neuroblastoma cells in culture: a model for neuronal cell differentiation
and function. Acta Physiol Scand Suppl 592: 25–37.
4. Liu S, Tian Y, Chlenski A, Yang Q, Salwen HR, et al. (2005) ‘Cross-talk’
between Schwannian stroma and neuroblasts promotes neuroblastoma tumor
differentiation and inhibits angiogenesis. Cancer Lett 228: 125–131.
5. Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt V, et al. (2005)
Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer
Lett 228: 143–153.
6. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, et al. (1999)
Terminology and morphologic criteria of neuroblastic tumors: recommenda-
tions by the International Neuroblastoma Pathology Committee. Cancer 86:
349–363.
7. Edsjo A, Holmquist L, Pahlman S (2007) Neuroblastoma as an experimental
model for neuronal differentiation and hypoxia-induced tumor cell dedifferen-
tiation. Semin Cancer Biol 17: 248–256.
8. Hedborg F, Holmgren L, Sandstedt B, Ohlsson R (1994) The cell type-specific
IGF2 expression during early human development correlates to the pattern of
overgrowth and neoplasia in the Beckwith-Wiedemann syndrome. Am J Pathol
145: 802–817.
9. Hedborg F, Ohlsson R, Sandstedt B, Grimelius L, Hoehner JC, et al. (1995)
IGF2 expression is a marker for paraganglionic/SIF cell differentiation in
neuroblastoma. Am J Pathol 146: 833–847.
10. Hoehner JC, Hedborg F, Eriksson L, Sandstedt B, Grimelius L, et al. (1998)
Developmental gene expression of sympathetic nervous system tumors reflects
their histogenesis. Lab Invest 78: 29–45.
11. Hedborg F, Franklin G, Norrman J, Grimelius L, Wassberg E, et al. (2001)
Evidence of chromaffin oxygen sensing in neuroblastoma. Med Pediatr Oncol
36: 149–153.
12. Hedborg F, Ulleras E, Grimelius L, Wassberg E, Maxwell PH, et al. (2003)
Evidence for hypoxia-induced neuronal-to-chromaffin metaplasia in neuroblas-
toma. FASEB J 17: 598–609.
13. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on
human cancer. Nat Rev Cancer 8: 967–975.
14. Siemann DW (1998) The tumor microenvironment: a double-edged sword.
Int J Radiat Oncol Biol Phys 42: 697–699.
15. Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev
Cancer 2: 38–47.
16. Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Activation of the HIF pathway in
cancer. Curr Opin Genet Dev 11: 293–299.
17. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair
and genetic instability. Nat Rev Cancer 8: 180–192.
18. Lunt SJ, Chaudary N, Hill RP (2008) The tumor microenvironment and
metastatic disease. Clin Exp Metastasis.
19. Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin
Oncol 25: 4066–4074.
20. Sullivan R, Graham CH (2007) Hypoxia-driven selection of the metastatic
phenotype. Cancer Metastasis Rev 26: 319–331.
21. Vaupel P (2004) Tumor microenvironmental physiology and its implications for
radiation oncology. Semin Radiat Oncol 14: 198–206.
22. Pahlman S, Hedborg F (2000) Development of the neural crest and sympathetic
nervous system. In: Brodeur GM ST, Tsuchida Y, Vouˆte PA, eds.
Neuroblastoma. Amsterdam: Elsevier. pp 9–19.
23. Feldman SA, Eiden LE (2003) The chromogranins: their roles in secretion from
neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr
Pathol 14: 3–23.
24. Winkler H, Fischer-Colbrie R (1992) The chromogranins A and B: the first 25
years and future perspectives. Neuroscience 49: 497–528.
25. Fischer-Colbrie R, Eder S, Lovisetti-Scamihorn P, Becker A, Laslop A (2002)
Neuroendocrine secretory protein 55: a novel marker for the constitutive
secretory pathway. Ann N Y Acad Sci 971: 317–322.
26. Li JY, Lovisetti-Scamihorn P, Fischer-Colbrie R, Winkler H, Dahlstrom A
(2002) Distribution and intraneuronal trafficking of a novel member of the
chromogranin family, NESP55, in the rat peripheral nervous system.
Neuroscience 110: 731–745.
27. Jakobsen AM, Ahlman H, Kolby L, Abrahamsson J, Fischer-Colbrie R, et al.
(2003) NESP55, a novel chromogranin-like peptide, is expressed in endocrine
tumours of the pancreas and adrenal medulla but not in ileal carcinoids.
Br J Cancer 88: 1746–1754.
28. Valentiner U, Valentiner FU, Schumacher U (2008) Expression of CD44 is
associated with a metastatic pattern of human neuroblastoma cells in a SCID
mouse xenograft model. Tumour Biol 29: 152–160.
29. Andrae J, Molander C, Smits A, Funa K, Nister M (2002) Platelet-derived
growth factor-B and -C and active alpha-receptors in medulloblastoma cells.
Biochem Biophys Res Commun 296: 604–611.
30. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, et al. (1993)
Revisions of the international criteria for neuroblastoma diagnosis, staging, and
response to treatment. J Clin Oncol 11: 1466–1477.
31. Weiss U, Ischia R, Eder S, Lovisetti-Scamihorn P, Bauer R, et al. (2000)
Neuroendocrine secretory protein 55 (NESP55): alternative splicing onto
transcripts of the GNAS gene and posttranslational processing of a maternally
expressed protein. Neuroendocrinology 71: 177–186.
32. Ohlsson R, Holmgren L, Glaser A, Szpecht A, Pfeifer-Ohlsson S (1989) Insulin-
like growth factor 2 and short-range stimulatory loops in control of human
placental growth. EMBO J 8: 1993–1999.
33. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, et al. (2000) The
expression and distribution of the hypoxia-inducible factors HIF-1alpha and
HIF-2alpha in normal human tissues, cancers, and tumor-associated macro-
phages. Am J Pathol 157: 411–421.
34. Taxi J, Domich A-M (1983) Morphology and histophysiology of SIF cells in the
autonomic ganglia. In: L-G E, ed. Chichester: Wiley-Interscience. pp 67–95.
35. Coupland RE (1965) The Natural History of the Chromaffin Cell. London:
Longmans Green.
36. Maxwell PH (2005) Hypoxia-inducible factor as a physiological regulator. Exp
Physiol 90: 791–797.
37. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differential roles of
hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene
regulation. Mol Cell Biol 23: 9361–9374.
38. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, et al. (1998)
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and
comparison with hypoxia-inducible factor-1alpha. Blood 92: 2260–2268.
39. Jurgensen JS, Rosenberger C, Wiesener MS, Warnecke C, Horstrup JH, et al.
(2004) Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and
stromal cells of ischemic myocardium. FASEB J 18: 1415–1417.
40. Pahlman S, Stockhausen MT, Fredlund E, Axelson H (2004) Notch signaling in
neuroblastoma. Semin Cancer Biol 14: 365–373.
41. Fredlund E, Ovenberger M, Borg K, Pahlman S (2008) Transcriptional
adaptation of neuroblastoma cells to hypoxia. Biochem Biophys Res Commun
366: 1054–1060.
42. Benowitz LI, Routtenberg A (1997) GAP-43: an intrinsic determinant of
neuronal development and plasticity. Trends Neurosci 20: 84–91.
43. Gestblom C, Hoehner JC, Hedborg F, Sandstedt B, Pahlman S (1997) In vivo
spontaneous neuronal to neuroendocrine lineage conversion in a subset of
neuroblastomas. Am J Pathol 150: 107–117.
44. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, et al. (2002) Hypoxia alters
gene expression in human neuroblastoma cells toward an immature and neural
crest-like phenotype. Proc Natl Acad Sci U S A 99: 7021–7026.
45. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL (1998) The
hypoxia-responsive transcription factor EPAS1 is essential for catecholamine
homeostasis and protection against heart failure during embryonic development.
Genes Dev 12: 3320–3324.
46. Hervonen A, Korkala O (1972) The effect of hypoxia on the catecholamine
content of human fetal abdominal paraganglia and adrenal medulla. Acta
Obstet Gynecol Scand 51: 17–24.
47. Axelson H (2004) The Notch signaling cascade in neuroblastoma: role of the
basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett 204: 171–178.
NESP55 in Neuroblastoma
PLoS ONE | www.plosone.org 15 September 2010 | Volume 5 | Issue 9 | e12825
